Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28264858 | 0.96 | — | — | |
| SCHEMBL5847104 | 0.77 | — | — | |
| SCHEMBL6744089 | 0.77 | NOS1 (0.31) | — | |
| SCHEMBL11735839 | 0.76 | — | — | |
| SCHEMBL27303956 | 0.74 | — | — | |
| SCHEMBL623332 | 0.71 | — | — | |
| SCHEMBL7514916 | 0.65 | — | — | |
| Nitric Acid SCHEMBL6553646 | 0.64 | — | — | |
| SCHEMBL566952 | 0.62 | ALDH1A1 (0.42) | ALDH1A1TP53 | |
| SCHEMBL246529 | 0.62 | ALDH1A1 (0.31) | ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| US-11685895-B2 | Method for manufacturing microalgae micro powder containing astaxanthin and fatty acids with enhanced penetration performance and food availability | SONG, SUNG EUN (KR) | 2023-06-27 | — | — | US | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| US-20210189324-A1 | METHOD FOR MANUFACTURING MICROALGAE MICRO POWDER CONTAINING ASTAXANTHIN AND FATTY ACIDS WITH ENHANCED PENETRATION PERFORMANCE AND FOOD AVAILABILITY | SONG SUNG EUN (KR) | 2021-06-24 | — | — | US | claimed |
| CN-112877323-A | Method for screening high-yield cellulase filamentous fungi through self-adaptive mutagenesis | 厦门大学 | 2021-06-01 | — | — | CN | claimed |
| CN-109758483-A | The preparation method of murine chronic atrophic gastritis model | 右江民族医学院 | 2019-05-17 | — | — | CN | claimed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | claimed |
| CN-109010379-A | The preparation method of atrophic gastritis animal model | 右江民族医学院 | 2018-12-18 | — | — | CN | claimed |
| WO-2017042634-A2 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE | DEL MAR PHARMACEUTICALS (CA) | 2017-03-16 | — | — | WO | claimed |
| EP-2616547-A1 | PROCESS FOR PRODUCTION OF L-FUCOSE | INALCO S.A.S. Di Giovanni Cipoletti & C. (IT) | 2013-07-24 | — | — | EP | claimed |
| EP-1786262-A1 | METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH | Ingenium Pharmaceuticals AG (DE) | 2007-05-23 | — | — | EP | claimed |
| EP-1778835-A1 | METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH | Ingenium Pharmaceuticals AG (DE) | 2007-05-02 | — | — | EP | claimed |
| US-20070029529-A1 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | KOMATSU AKIHIKO | 2007-02-08 | — | — | US | claimed |
| WO-2006027231-A1 | METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH | INGENIUM PHARMACEUTICALS AG (DE) | 2006-03-16 | — | — | WO | claimed |
| WO-2006018316-A1 | METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH | INGENIUM PHARMACEUTICALS AG (DE) | 2006-02-23 | — | — | WO | claimed |
| WO-2006002902-A2 | METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH | INGENIUM PHARMACEUTICALS AG (DE) | 2006-01-12 | — | — | WO | claimed |
| WO-2005107447-A2 | METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH | INGENIUM PHARMACEUTICALS AG (DE) | 2005-11-17 | — | — | WO | claimed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
| WO-1992012732-A1 | LIVE VACCINE AGAINST COLIBACILLOSIS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1992-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | ALDH1A1 2307/4885TP53 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.